Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 618

1.

Distributed neural efficiency: Intelligence and age modulate adaptive allocation of resources in the brain.

Ramchandran K, Zeien E, Andreasen NC.

Trends Neurosci Educ. 2019 Jun;15:48-61. doi: 10.1016/j.tine.2019.02.006. Epub 2019 Mar 19.

PMID:
31176471
2.

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein.

Zettergren A, Höglund K, Kern S, Thorvaldsson V, Johan Skoog M, Hansson O, Andreasen N, Bogdanovic N, Blennow K, Skoog I, Zetterberg H.

Sci Rep. 2019 Feb 21;9(1):2460. doi: 10.1038/s41598-018-36650-3.

3.

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.

Leuzy A, Cicognola C, Chiotis K, Saint-Aubert L, Lemoine L, Andreasen N, Zetterberg H, Ye K, Blennow K, Höglund K, Nordberg A.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1152-1163. doi: 10.1007/s00259-018-4242-6. Epub 2019 Jan 4.

4.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.

Timmers M, Streffer JR, Russu A, Tominaga Y, Shimizu H, Shiraishi A, Tatikola K, Smekens P, Börjesson-Hanson A, Andreasen N, Matias-Guiu J, Baquero M, Boada M, Tesseur I, Tritsmans L, Van Nueten L, Engelborghs S.

Alzheimers Res Ther. 2018 Aug 23;10(1):85. doi: 10.1186/s13195-018-0415-6.

5.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E.

N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971.

6.

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.

Landen JW, Andreasen N, Cronenberger CL, Schwartz PF, Börjesson-Hanson A, Östlund H, Sattler CA, Binneman B, Bednar MM.

Alzheimers Dement (N Y). 2017 Jun 8;3(3):393-401. doi: 10.1016/j.trci.2017.05.003. eCollection 2017 Sep.

7.

Delta-frequency stimulation of cerebellar projections can compensate for schizophrenia-related medial frontal dysfunction.

Parker KL, Kim YC, Kelley RM, Nessler AJ, Chen KH, Muller-Ewald VA, Andreasen NC, Narayanan NS.

Mol Psychiatry. 2017 May;22(5):647-655. doi: 10.1038/mp.2017.50. Epub 2017 Mar 28.

8.

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.

Herukka SK, Simonsen AH, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):285-295. doi: 10.1016/j.jalz.2016.09.009. Epub 2016 Oct 27. Review.

9.

Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.

Simonsen AH, Herukka SK, Andreasen N, Baldeiras I, Bjerke M, Blennow K, Engelborghs S, Frisoni GB, Gabryelewicz T, Galluzzi S, Handels R, Kramberger MG, Kulczyńska A, Molinuevo JL, Mroczko B, Nordberg A, Oliveira CR, Otto M, Rinne JO, Rot U, Saka E, Soininen H, Struyfs H, Suardi S, Visser PJ, Winblad B, Zetterberg H, Waldemar G.

Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27. Review.

10.

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury.

Shahim P, Gren M, Liman V, Andreasson U, Norgren N, Tegner Y, Mattsson N, Andreasen N, Öst M, Zetterberg H, Nellgård B, Blennow K.

Sci Rep. 2016 Nov 7;6:36791. doi: 10.1038/srep36791.

11.

Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.

Padayachee ER, Zetterberg H, Portelius E, Borén J, Molinuevo JL, Andreasen N, Cukalevski R, Linse S, Blennow K, Andreasson U.

Brain Res. 2016 Nov 15;1651:11-16. doi: 10.1016/j.brainres.2016.09.022. Epub 2016 Sep 23.

12.

Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.

Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B.

Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16.

13.

[Acute pain and loss of strength in the lower limb].

Al-Bakri M, Michalska B, Molzen A, Dalgaard D, Andreasen N.

Ugeskr Laeger. 2016 Jul 18;178(29). pii: V67782. Danish. No abstract available.

PMID:
27460469
14.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.

Andersson CH, Hansson O, Minthon L, Andreasen N, Blennow K, Zetterberg H, Skoog I, Wallin A, Nilsson S, Kettunen P.

J Alzheimers Dis. 2016 Jul 1;53(4):1353-63. doi: 10.3233/JAD-160319.

15.

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.

Eyjolfsdottir H, Eriksdotter M, Linderoth B, Lind G, Juliusson B, Kusk P, Almkvist O, Andreasen N, Blennow K, Ferreira D, Westman E, Nennesmo I, Karami A, Darreh-Shori T, Kadir A, Nordberg A, Sundström E, Wahlund LO, Wall A, Wiberg M, Winblad B, Seiger Å, Wahlberg L, Almqvist P.

Alzheimers Res Ther. 2016 Jul 7;8(1):30. doi: 10.1186/s13195-016-0195-9.

16.

Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.

Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C, Mollenhauer B, Parnetti L, Chiasserini D, Molinuevo JL, Perret-Liaudet A, Verbeek MM, Andreasen N, Brosseron F, Bahl JM, Herukka SK, Hausner L, Frölich L, Labonte A, Poirier J, Miller AM, Zilka N, Kovacech B, Urbani A, Suardi S, Oliveira C, Baldeiras I, Dubois B, Rot U, Lehmann S, Skinningsrud A, Betsou F, Wiltfang J, Gkatzima O, Winblad B, Buchfelder M, Kornhuber J, Lewczuk P.

J Alzheimers Dis. 2016 Mar 1;52(1):51-64. doi: 10.3233/JAD-150883.

PMID:
26967210
17.

HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain.

García-Ayllón MS, Botella-López A, Cuchillo-Ibañez I, Rábano A, Andreasen N, Blennow K, Ávila J, Sáez-Valero J.

Mol Neurobiol. 2017 Jan;54(1):188-199. doi: 10.1007/s12035-015-9644-x. Epub 2016 Jan 6.

PMID:
26738850
18.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

19.

Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.

Nordberg A, Kadir A, Andreasen N, Almkvist O, Wall A, Långström B, Zetterberg H.

J Alzheimers Dis. 2015;47(3):691-704. doi: 10.3233/JAD-132474.

PMID:
26401704
20.

Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.

Slemmon JR, Shapiro A, Mercken M, Streffer J, Romano G, Andreasen N, Zetterberg H, Blennow K.

J Neurochem. 2015 Dec;135(5):1049-58. doi: 10.1111/jnc.13297. Epub 2015 Sep 29.

21.

John and Alicia Nash: A Beautiful Love Story.

Andreasen NC.

Am J Psychiatry. 2015 Aug 1;172(8):710-3. doi: 10.1176/appi.ajp.2015.15060709. No abstract available.

PMID:
26234595
22.

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease.

Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, Caputo A, Winblad B, Graf A.

Alzheimers Res Ther. 2015 Apr 27;7(1):23. doi: 10.1186/s13195-015-0108-3. eCollection 2015.

23.

Childhood-onset schizophrenia case with 2.2 Mb deletion at chromosome 3p12.2-p12.1 and two large chromosomal abnormalities at 16q22.3-q24.3 and Xq23-q28.

Rudd D, Axelsen M, Epping EA, Andreasen N, Wassink T.

Clin Case Rep. 2015 Apr;3(4):201-7. doi: 10.1002/ccr3.192. Epub 2015 Feb 2.

24.

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC.

PLoS One. 2015 Mar 19;10(3):e0098153. doi: 10.1371/journal.pone.0098153. eCollection 2015.

25.

Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease.

Karami A, Eyjolfsdottir H, Vijayaraghavan S, Lind G, Almqvist P, Kadir A, Linderoth B, Andreasen N, Blennow K, Wall A, Westman E, Ferreira D, Kristoffersen Wiberg M, Wahlund LO, Seiger Å, Nordberg A, Wahlberg L, Darreh-Shori T, Eriksdotter M.

Alzheimers Dement. 2015 Nov;11(11):1316-28. doi: 10.1016/j.jalz.2014.11.008. Epub 2015 Feb 9.

PMID:
25676388
26.

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K.

Alzheimers Dement. 2015 Oct;11(10):1180-90. doi: 10.1016/j.jalz.2014.10.009. Epub 2014 Dec 19.

PMID:
25533203
27.

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.

Lleó A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B.

Nat Rev Neurol. 2015 Jan;11(1):41-55. doi: 10.1038/nrneurol.2014.232. Epub 2014 Dec 16. Review.

PMID:
25511894
28.

The therapeutic potential of the cerebellum in schizophrenia.

Parker KL, Narayanan NS, Andreasen NC.

Front Syst Neurosci. 2014 Sep 15;8:163. doi: 10.3389/fnsys.2014.00163. eCollection 2014.

29.

A genome-wide CNV analysis of schizophrenia reveals a potential role for a multiple-hit model.

Rudd DS, Axelsen M, Epping EA, Andreasen NC, Wassink TH.

Am J Med Genet B Neuropsychiatr Genet. 2014 Dec;165B(8):619-26. doi: 10.1002/ajmg.b.32266. Epub 2014 Sep 16.

PMID:
25228354
30.

Effects of age on white matter integrity and negative symptoms in schizophrenia.

Bijanki KR, Hodis B, Magnotta VA, Zeien E, Andreasen NC.

Schizophr Res. 2015 Jan;161(1):29-35. doi: 10.1016/j.schres.2014.05.031. Epub 2014 Jun 20.

31.

Pathways to Alzheimer's disease.

Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H.

J Intern Med. 2014 Mar;275(3):296-303. doi: 10.1111/joim.12192. Review.

32.

The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?

Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM.

Alzheimers Dement. 2014 Nov;10(6):713-723.e2. doi: 10.1016/j.jalz.2013.12.023. Epub 2014 Apr 8.

PMID:
24721526
33.

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.

Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, Yeo A, Khan S, Loercher A, Chalker M, Hottenstein C, Zetterberg H, Hilpert J, Mistry P.

Alzheimers Res Ther. 2014 Apr 9;6(2):19. doi: 10.1186/alzrt249. eCollection 2014.

34.

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M.

J Intern Med. 2014 Mar;275(3):251-83. doi: 10.1111/joim.12191. Review.

35.

Vitamin D in relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes.

Hooshmand B, Lökk J, Solomon A, Mangialasche F, Miralbell J, Spulber G, Annerbo S, Andreasen N, Winblad B, Cedazo-Minguez A, Wahlund LO, Kivipelto M.

J Gerontol A Biol Sci Med Sci. 2014 Sep;69(9):1132-8. doi: 10.1093/gerona/glu022. Epub 2014 Feb 25.

PMID:
24568931
36.

Active immunotherapy options for Alzheimer's disease.

Winblad B, Graf A, Riviere ME, Andreasen N, Ryan JM.

Alzheimers Res Ther. 2014 Jan 30;6(1):7. doi: 10.1186/alzrt237. eCollection 2014. Review.

37.

The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data.

Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann O, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CR, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJ, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Göring HH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR Jr, Jenkinson M, Johnston C, Jönsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Krämer B, Kwok JB, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaître H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdusamy A, Luciano M, Macciardi F, Machielsen MW, Macqueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer-Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Muñoz Maniega S, Mühleisen TW, Müller-Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou-Tsiridou M, Papmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Pütz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz-Santiañez R, Romanczuk-Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork AJ, Schulz SC, Schür R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Sämann PG, Teumer A, Toga AW, Tordesillas-Gutierrez D, Trabzuni D, Trost S, Turner J, Van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TG, van Haren NE, van 't Ent D, van Tol MJ, Valdés Hernández MC, Veltman DJ, Versace A, Völzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W; Alzheimer’s Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group.

Brain Imaging Behav. 2014 Jun;8(2):153-82. doi: 10.1007/s11682-013-9269-5. Review.

38.

CSF Presenilin-1 complexes are increased in Alzheimer's disease.

García-Ayllón MS, Campanari ML, Brinkmalm G, Rábano A, Alom J, Saura CA, Andreasen N, Blennow K, Sáez-Valero J.

Acta Neuropathol Commun. 2013 Aug 6;1:46. doi: 10.1186/2051-5960-1-46.

39.

The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

J Intern Med. 2014 Apr;275(4):418-27. doi: 10.1111/joim.12164. Epub 2013 Dec 11.

40.

[Treatment of early stages of Alzheimer's disease: New guidelines are in the pipeline].

Winblad B, Kivipelto M, Andersen P, Johansson G, Andreasen N.

Lakartidningen. 2013 Sep 11-17;110(37):1613. Swedish. No abstract available.

PMID:
24163935
41.

Automated parcellation of the brain surface generated from magnetic resonance images.

Li W, Andreasen NC, Nopoulos P, Magnotta VA.

Front Neuroinform. 2013 Oct 22;7:23. doi: 10.3389/fninf.2013.00023. eCollection 2013.

42.

Eyeblink conditioning in unmedicated schizophrenia patients: a positron emission tomography study.

Parker KL, Andreasen NC, Liu D, Freeman JH, O'Leary DS.

Psychiatry Res. 2013 Dec 30;214(3):402-9. doi: 10.1016/j.pscychresns.2013.07.006. Epub 2013 Oct 1.

43.

Consensus paper: the cerebellum's role in movement and cognition.

Koziol LF, Budding D, Andreasen N, D'Arrigo S, Bulgheroni S, Imamizu H, Ito M, Manto M, Marvel C, Parker K, Pezzulo G, Ramnani N, Riva D, Schmahmann J, Vandervert L, Yamazaki T.

Cerebellum. 2014 Feb;13(1):151-77. doi: 10.1007/s12311-013-0511-x.

44.

The glial marker YKL-40 is decreased in synucleinopathies.

Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H.

Mov Disord. 2013 Nov;28(13):1882-5. doi: 10.1002/mds.25589. Epub 2013 Jul 11.

PMID:
23847144
45.

Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren's syndrome.

Dehlin M, Bjersing J, Erlandsson M, Andreasen N, Zetterberg H, Mannerkorpi K, Bokarewa M.

Scand J Rheumatol. 2013;42(5):394-9. doi: 10.3109/03009742.2013.809143. Epub 2013 Jul 10.

PMID:
23837643
46.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K.

PLoS One. 2013 Jun 14;8(6):e66381. doi: 10.1371/journal.pone.0066381. Print 2013.

47.

Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S.

Neurosci Biobehav Rev. 2013 Sep;37(8):1680-91. doi: 10.1016/j.neubiorev.2013.06.001. Epub 2013 Jun 14.

48.

The MCIC collection: a shared repository of multi-modal, multi-site brain image data from a clinical investigation of schizophrenia.

Gollub RL, Shoemaker JM, King MD, White T, Ehrlich S, Sponheim SR, Clark VP, Turner JA, Mueller BA, Magnotta V, O'Leary D, Ho BC, Brauns S, Manoach DS, Seidman L, Bustillo JR, Lauriello J, Bockholt J, Lim KO, Rosen BR, Schulz SC, Calhoun VD, Andreasen NC.

Neuroinformatics. 2013 Jul;11(3):367-88. doi: 10.1007/s12021-013-9184-3.

49.

Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.

Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC.

Am J Psychiatry. 2013 Jun;170(6):609-15. doi: 10.1176/appi.ajp.2013.12050674. Erratum in: Am J Psychiatry. 2013 Jun 1;170(6):689.

50.

Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD.

Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.

Sci Rep. 2013;3:1339. doi: 10.1038/srep01339.

Supplemental Content

Loading ...
Support Center